CDC42 and Alzheimer disease: In contrast to the benefits of Rho GTPase inhibition in alleviating AD or ALS phenotypes in animal models, CNF1 constitutively activates RhoA, Rac1, and Cdc42, thus leading to remodeling of the actin cytoskeleton in intact cells.